Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

This bill requires New Jersey's Medicaid program (NJ FamilyCare) to pay inpatient hospitals the same reimbursement rate for long-acting injectable antipsychotic drugs as is paid for the same drugs in outpatient settings. It mandates that this reimbursement be separate from standard hospital payment systems (like DRGs) and based on the actual drug cost, not a fixed hospital payment. The policy directly affects inpatient providers (such as hospitals) treating patients with serious mental illnesses like schizophrenia or bipolar disorder. The change aims to better align reimbursement with the true cost of these drugs, which can improve patient access and outcomes by reducing hospital readmissions.